细胞衰老在慢性心力衰竭中的作用机制研究进展

doi:10.3969/j.issn.1003-9198.2025.01.021

摘要/Abstract

摘要： 慢性心力衰竭(CHF)是心脏疾病的终末期发展阶段,临床上可由多种因素诱发,死亡率高,预后差。近年来人们发现,CHF的发生风险随着年龄的增加、细胞的衰老而增加,细胞衰老在CHF的发生发展中发挥重要的作用。因此,本文从不同类型的细胞衰老与CHF的关系综述细胞衰老在CHF中的作用与治疗进展,以期为CHF的研究和治疗提供新思路。

关键词: 细胞衰老, 慢性心力衰竭, 作用机制

Abstract: Chronic heart failure (CHF) is the end stage of heart disease, which can be induced by various factors, with high mortality and poor prognosis. In recent years, it has been found that the risk of CHF increases with age and cell senescence, which plays an important role in CHF. Therefore, this article reviews the role and therapeutic progress of cellular senescence in CHF through the relationship between different types of cellular senescence and CHF, in order to provide new insights for the research and treatment of CHF.

Key words: cellular senescence, chronic heart failure, mechanism

中图分类号:

R 541.6

赵淑晴, 赵莹, 张宇, 卢笑晖. 细胞衰老在慢性心力衰竭中的作用机制研究进展[J]. 实用老年医学, 2025, 39(1): 93-97.

ZHAO Shuqing, ZHAO Ying, ZHANG Yu, LU Xiaohui. A review of cellular senescence in chronic heart failure[J]. Practical Geriatrics, 2025, 39(1): 93-97.

参考文献

[1] ŠPINAR J, ŠPINAROVÁ L, VÍTOVEC J. Pathophysiology, causes and epidemiology of chronic heart failure[J]. Vnitr Lek, 2018, 64(9):834-838.
[2] METRA M, TOMASONI D, ADAMO M, et al. Worsening of chronic heart failure:definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2023, 25(6):776-791.
[3] Writing committee of the report on cardiovascular health and diseases in China. Report on cardiovascular health and diseases in China 2021:an updated summary[J]. Biomed Environ Sci, 2022, 35(7):573-603.
[4] MCDONAGH T A, METRA M, ADAMO M,et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37):3627-3639.
[5] HERKERT C, MIGEOTTE P F, HOSSEIN A, et al. The kinocardiograph for assessment of changes in haemodynamic load in patients with chronic heart failure with reduced ejection fraction[J]. ESC Heart Fail, 2021, 8(6):4925-4932.
[6] 周刚,吴辉,刘滴,等.心肌细胞衰老及其保护策略的研究进展[J].中华老年心脑血管病杂志, 2021, 23(7):772-774.
[7] ALAM P, HAILE B, ARIF M, et al. Inhibition of senescence-associated genes Rb1 and Meis2 in adult cardiomyocytes results in cell cycle reentry and cardiac repair post-myocardial infarction[J]. J Am Heart Assoc, 2019, 8(15):e012089.
[8] JANKAUSKAS S S, KANSAKAR U, VARZIDEH F, et al. Heart failure in diabetes[J]. Metabolism, 2021, 125:154910.
[9] ANDERSON R, LAGNADO A, MAGGIORANI D, et al. Length-independent telomere damage drives post-mitotic cardiomyocyte senescence[J]. EMBO J, 2019, 38(5):e100492.
[10] 赵卓. 长链非编码RNA XIST在心肌肥厚中的作用及机制研究[D]. 长春: 吉林大学, 2021.
[11] FRANTZ S, HUNDERTMARK M J, SCHULZ-MENGER J, et al. Left ventricular remodelling post-myocardial infarction:pathophysiology, imaging, and novel therapies[J]. Eur Heart J, 2022, 43(27):2549-2561.
[12] STRAIT J B, LAKATTA E G. Aging-associated cardiovascular changes and their relationship to heart failure[J]. Heart Fail Clin, 2012, 8(1):143-164.
[13] URYGA A K, BENNETT M R. Ageing induced vascular smooth muscle cell senescence in atherosclerosis[J]. J Physiol, 2016, 594(8):2115-2124.
[14] ZHANG L, LIU M, LIU W, et al. Th17/IL-17 induces endothelial cell senescence via activation of NF-κB/p53/Rb signaling pathway[J]. Lab Invest, 2021,101(11):1418-1426.
[15] XUE G L, LI D S, WANG Z Y, et al. Interleukin-17 upregulation participates in the pathogenesis of heart failure in mice via NF-κB-dependent suppression of SERCA2a and Cav1.2 expression[J]. Acta Pharmacol Sin, 2021, 42(11):1780-1789.
[16] HOHENSINNER P J, KAUN C, BUCHBERGER E, et al. Age intrinsic loss of telomere protection via TRF1 reduction in endothelial cells[J]. Biochim Biophys Acta, 2016, 1863(2):360-367.
[17] GEVAERT A B, SHAKERI H, LELOUP A J, et al. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model[J]. Circ Heart Fail, 2017, 10(6):e003806.
[18] LACOLLEY P, REGNAULT V, NICOLETTI A, et al. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles[J]. Cardiovasc Res, 2012, 95(2):194-204.
[19] GROOTAERT M O J, MOULIS M, ROTH L, et al. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis[J]. Cardiovasc Res, 2018, 114(4):622-634.
[20] GARDNER S E, HUMPHRY M, BENNETT M R, et al. Senescent vascular smooth muscle cells drive inflammation through an interleukin-1α-dependent senescence-associated secretory phenotype[J]. Arterioscler Thromb Vasc Biol, 2015, 35(9):1963-1974.
[21] GALLO S, VITACOLONNA A, BONZANO A, et al. ERK:a key player in the pathophysiology of cardiac hypertrophy[J]. Int J Mol Sci, 2019, 20(9):2164.
[22] TALLQUIST M D. Cardiac fibroblast diversity[J]. Annu Rev Physiol, 2020, 82:63-78.
[23] ZHAO P, SUN T, LYU C, et al. Cell mediated ECM-degradation as an emerging tool for anti-fibrotic strategy[J]. Cell Regen, 2023, 12(1):29.
[24] TRIAL J, ENTMAN M L, CIESLIK K A. Mesenchymal stem cell-derived inflammatory fibroblasts mediate interstitial fibrosis in the aging heart[J]. J Mol Cell Cardiol, 2016, 91:28-34.
[25] KO T, NOMURA S, YAMADA S, et al. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF-β-IGFBP7 axis[J]. Nat Commun, 2022, 13(1):3275.
[26] TANG X, LI P H, CHEN H Z. Cardiomyocyte senescence and cellular communications within myocardial microenvironments[J]. Front Endocrinol: Lausanne, 2020, 11:280.
[27] SADIGHI AKHA A A. Aging and the immune system:an overview[J]. J Immunol Methods, 2018, 463:21-26.
[28] LAGNADO A, LESLIE J, RUCHAUD-SPARAGANO M H, et al. Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner[J]. EMBO J, 2021, 40(9):e106048.
[29] 邱雨璐,刘牧,王灵冰, 等.中性粒细胞免疫衰老与老年病的相关性研究进展[J].中国老年学杂志, 2019, 39(8):2019-2023.
[30] BRAUNING A, RAE M, ZHU G, et al. Aging of the immune system: focus on natural killer cells phenotype and functions[J]. Cells, 2022, 11(6):1017.
[31] HAK Ł, MYŚLIWSKA J, WIÉCKIEWICZ J, et al. NK cell compartment in patients with coronary heart disease[J]. Immun Ageing, 2007, 4:3.
[32] SHIRAKAWA K, SANO M. T Cell Immunosenescence in aging, obesity, and cardiovascular disease[J]. Cells, 2021, 10(9):2435.
[33] SPYRIDOPOULOS I, HOFFMANN J, AICHER A, et al. Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity[J]. Circulation, 2009, 120(14):1364-1372.
[34] XYDONAS S, PARISSIS J, LIONI L, et al. Immunosenescence in patients with chronic systolic heart failure[J]. J Cardiovasc Med :Hagerstown, 2016, 17(8):624-630.
[35] SEEGER T, HAFFEZ F, FISCHER A, et al. Immunosenescence-associated microRNAs in age and heart failure[J]. Eur J Heart Fail, 2013, 15(4):385-393.
[36] LEE G H, HOANG T H, JUNG E S, et al. Anthocyanins attenuate endothelial dysfunction through regulation of uncoupling of nitric oxide synthase in aged rats[J]. Aging Cell, 2020, 19(12):e13279.
[37] TAO Z, ZHANG R, ZUO W, et al. Association between dietary intake of anthocyanidins and heart failure among American adults: NHANES (2007-2010 and 2017-2018)[J]. Front Nutr, 2023, 10:1107637.
[38] ZHANG P, TOU F, ZHAN Y, et al. Oxidative stress and pyroptosis in doxorubicin-induced heart failure and atrial fibrillation[J]. Oxid Med Cell Longev, 2023, 2023:4938287.
[39] RAJ P, THANDAPILLY S J, WIGLE J, et al. A comprehensive analysis of the efficacy of resveratrol in atherosclerotic cardiovascular disease, myocardial infarction and heart failure[J]. Molecules, 2021, 26(21):6600.
[40] JIA K, DAI Y, LIU A, et al. Senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice[J]. J Cardiovasc Pharmacol, 2020, 76(4):452-460.
[41] CHEN M S, LEE R T, GARBERN J C. Senescence mechanisms and targets in the heart[J]. Cardiovasc Res, 2022, 118(5):1173-1187.